Business
ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial
Experienced hematologist-oncologist to lead strategic and medical oversight of clinical developme...
About this update from Zyus Life Sciences Corporation
[{"type":"text","content":"ZYUS Life Sciences Strengthens Clinical Leadership with Appointment of Chief Medical Officer to Support Phase 2 Oncology Pain Trial\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n \n\n\n\n\n Experienced hematologist-oncologist to lead strategic and medical oversight of clinical development program\n \n\n\n\n\n ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company’s leadership team as Chief Medical Officer (“CMO”), effective July 14, 2025.\n \n\n Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academic experience based in Saskatoon, Saskatchewan, specializing in blood cancers and stem cell transplantation. As CMO, Dr. Stakiw will provide clinical leadership and oversee the scientific integrity of ZYUS’ clinical development program. Her appointment marks a significant step as the Company advances its lead drug product candidate, Trichomylin® softgel capsules, through its pivotal Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) trial.\n \n\n “Dr. Stakiw brings a wealth of clinical expertise and firsthand patient experience in oncology care, which is instrumental as we advance our Phase 2 UTOPIA trial,” said Brent Zettl, President and CEO of ZYUS. “Her strong understanding of research and treatment development will be invaluable in addressing the critical need for effective, non-opioid cancer pain therapies and supporting our commitment to improving patient outcomes.”\n \n\n “I’m pleased to take on the role of Chief Medical Officer at ZYUS,” said Dr. Julie Stakiw. “ZYUS’ commitment to developing innovative, non-opioid alternatives for cancer pain aligns with my passion for improving patient care. I look forward to contributing my clinical and research experience to support the advancement of the Phase 2 UTOPIA trial and help bring meaningful new options to patients facing cancer pain.”\n \n\n Dr. Stakiw completed her medical degree and internal medicine residency at the University of Saskatchewan, followed by ...